Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 23

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 23
---
 Expected Return to Shareholders if the Company is Liquidated — The Company believes that                                                                                                                                                                  
 the Consideration to be paid to the Shareholders in the Arrangement is more favorable to such holders than the potential value that might be distributable to the Shareholders if the Company were to effect a statutory liquidation, which conclusion    
 was based on a financial analysis performed by the Company’s management and, among other factors, the following: (i) an orderly liquidation would require that the Company continue to operate until a liquidation process could be completed,            
 which would likely require the Company to continue to incur costs as a publicly listed company that would reduce the cash available for distribution to the Shareholders; (ii) the Company’s directors and officers do not have substantial               
 experience with the liquidation of companies, which would necessitate engaging and compensating experienced consultants to assist with the liquidation effort, as well as incentivizing certain existing employees to remain with the Company through the 
 liquidation process; (iii) the Company would need to engage and compensate advisors and consultants to assist with efforts to                                                                                                                             |

7

| attempt to monetize the Company’s assets; and (iv) the Company would need to set aside cash for an extended period of time to be available to cover contingent liabilities in connection                                                      
 with a liquidation, during which extended period of time, the Shareholders would not receive any of such withheld cash, and any such contingent liabilities that emerged as actual liabilities would reduce the amount available for ultimate 
 distribution to the Shareholders.                                                                                                                                                                                                             |

| • |     | High Level of Transaction Certainty and No Required Regulatory Approvals — The Company believes that                                                                                
 the level of transaction certainty associated with the Arrangement is high, including as a result of its limited conditionality and the absence of any required regulatory filings. |

| • |     | Ability to Monetize Programs and Intellectual Property —  The Company retains the ability to                                                                                                                            
 monetize its programs and intellectual property prior to Closing, which may further enhance the value available for distribution to Shareholders at the Effective Time or following the Effective Time through the CVR. |

| • |     | Required Shareholder Approval —  The Arrangement Resolution requires approval of not                                                                                                                                                                                                                                                                                                                     
 less than (i) two-thirds of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special Meeting, and (ii) to the extent required under MI 61-101, a simple